{
  "dataset": "Strategic Signal — Corporate AI Data Transactions",
  "dataset_version": "1.0.22",
  "methodology_version": "1.0.0",
  "released_on": "2026-10-27",
  "observation_count": 22,
  "approved_record_count": 17,
  "change_type": "reviewed_addition",
  "previous_version": "1.0.21",
  "changes": [
    "SS-AIDT-2026-0020: Owner-approved publication under the locked methodology: Tempus licenses de-identified multimodal oncology records and related analysis access to Bristol Myers Squibb under a multi-year agreement with $137.5 million of fixed contractual payments. The separate Pathos neurology license is not combined, and undisclosed training rights remain undisclosed."
  ],
  "known_limits": [
    "Only human_reviewed records count as approved observations.",
    "Bundled commitments and pending bids are not dataset purchase prices."
  ]
}